研究 CA239-0006 是一項開放標籤、隨機第三期臨床試驗，比較 MRTX849 聯合 cetuximab 與化療在 KRAS G12C 突變結直腸癌患者第二線治療中的療效。
適應症：Advanced Colorectal Cancer、Metastatic Colorectal Cancer
收案條件
納入條件
- Histologically confirmed diagnosis of colorectal carcinoma with KRAS G12C mutation in tumor tissue.
- Prior receipt of 1st line treatment in advanced CRC with a fluoropyrimidine-based chemotherapy regimen containing either oxaliplatin or irinotecan, and radiographically documented progression of disease on or after treatment.
排除條件
- Prior treatment with a therapy targeting KRAS G12C mutation (e.g., AMG 510).
- Prior treatment with an anti-EGFR antibody (e.g., cetuximab or panitumumab).
- Active brain metastasis
收案條件維持 ClinicalTrials.gov 原始英文登錄資料，實際收案資格以研究團隊的正式評估與受試者同意書為準。資料來源：ClinicalTrials.gov，每兩週自動更新，最後同步：2026年10月8日。